Clovis rises after promising data in ovarian cancer drug trial

Clovis Oncology

12/09/2022 12:10

** Shares of Clovis Oncology Inc  CLVS.O  jump ~14% to $1.31
premarket
    ** Data from a late-stage trial with ovarian cancer patients
showed co's drug Rubraca, as a first line of treatment, 
improves survival without progression of the disease across
different subgroups when compared with placebo  urn:newsml:reuters.com:*:nBw7v9mL1a
    ** Drug already been approved by U.S. FDA as maintenance
treatment of recurrent ovarian, fallopian tube or primary
peritoneal cancer after it has disappeared following initial
therapy
    ** Adds data on combination of Rubraca with Bristol Myers
Squibb's  BMY.N  cancer drug Opdivo expected in Q1 next year
    ** As of last close, stock down 57.6% YTD

 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))